Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and SurvivalDik J. Kwekkeboom, Eric P. Krenning, Wouter W. de Herder et al.|Journal of Clinical Oncology|2008Cited by 1.4k
Radiolabeled Somatostatin Analog [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate in Patients With Endocrine Gastroenteropancreatic TumorsDik J. Kwekkeboom, Eric P. Krenning, P.P.M. Kooij et al.|Journal of Clinical Oncology|2005Cited by 659
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patientsDik J. Kwekkeboom, Eric P. Krenning, Willem H. Bakker et al.|European Journal of Nuclear Medicine and Molecular Imaging|2001Cited by 471
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceRoelf Valkema, Eric P. Krenning, Marion de Jong et al.|Seminars in Nuclear Medicine|2002Cited by 433
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.Roelf Valkema, Eric P. Krenning, Stanislas Pauwels et al.|PubMed|2005Cited by 334